BioAge Labs (BIOA) Cash & Current Investments (2023 - 2026)

BioAge Labs has disclosed Cash & Current Investments across 4 years of filings, most recently posting $383.2 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $383.2 million, up 19.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $383.2 million (up 19.66% YoY), and the FY2025 annual result was $281.1 million, down 20.67% from the prior year.
• Cash & Current Investments came in at $383.2 million for Q1 2026 at BioAge Labs, up from $281.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $383.2 million in Q1 2026 to a low of $25.0 million in Q4 2023.
• The 4-year median for Cash & Current Investments is $297.0 million (2025), against an average of $272.8 million.
• Across the five-year window, Cash & Current Investments jumped 1319.84% in 2024 and fell 20.67% in 2025, its largest moves.
• BioAge Labs' Cash & Current Investments stood at $25.0 million in 2023, then surged by 1319.84% to $354.3 million in 2024, then retreated by 20.67% to $281.1 million in 2025, then jumped by 36.32% to $383.2 million in 2026.
• The last three Cash & Current Investments figures came in at $383.2 million (Q1 2026), $281.1 million (Q4 2025), and $285.8 million (Q3 2025), per Business Quant data.